Image Response Assessment Team

图像响应评估团队（IRAT）共享资源 项目摘要 放射学最初是一门专门研究解剖可视化的学科。在癌症的背景下， 现代技术和创新将成像转变为一种非侵入性工具， 肿瘤大小和形状，但也询问肿瘤内的空间异质性的基础上， 放射学外观、代谢和生理学。图像响应评估的总体目标 团队（IRAT）共享资源旨在通过提供单一点来提高临床研究的科学质量 Moffitt癌症中心（MCC）成员可以访问传统和先进的定量图像 分析服务。为此，围绕三个具体目标开展工作，即：1）保持和 改善RECIST（实体瘤疗效评价标准）的高可靠性和快速周转时间 肿瘤）和其他标准肿瘤评估指标; 2）通过翻译改善MCC的治疗试验 放射组学和多参数MRI（mpMRI）分析成为交钥匙成像生物标志物的研究进展 服务;和3）为会员提供获得非传统成像终点的治疗试验。IRAT 由五名全职工作人员组成，提供基于图像的定量肿瘤指标，以支持研究者- 发起，合作小组，并在MCC行业赞助的临床试验，是国家的一部分， 癌症中心IRAT联盟。伊拉克援助团在军事协调委员会的使命中发挥重要作用， 癌症的预防和治疗，”通过提供必要的支持和服务， 和创新的成像终点纳入临床试验，并在整个过程中提供质量保证和控制， 产生科学有效结果的过程。随着治疗模式的快速发展， IRAT提供了改进的成像终点，以满足这些尖端研究的需求 MCC成员。IRAT见证了定量图像响应量的持续增加 提供的评估服务。共启动了298项需要进行影像学缓解评估的新试验 从2011财年的39家上升到2015财年的65家。为伊拉克援助部队建立基础设施， 寻求使用先进和/或研究性成像技术的其他受资助试验机会， 分析和新的生物标志物。例如，IRAT正在支持多个赠款申请，并资助 研究放射组学和mpMRI成像生物标志物的成员在回顾性和前瞻性研究中的项目 临床和临床前研究。在上一个项目期间，援助团为来自4个千年挑战中心的34名成员提供了服务 程序.会员的总体使用率为94%，其中63%的总使用率支持会员与同行- 审查资金。IRAT支持的研究共产生了62篇同行评审的科学出版物， 此期间

Image Response Assessment Team (IRAT) Shared Resource PROJECT SUMMARY Radiology began as a discipline that specialized in the visualization of anatomy. In the context of cancer, modern technologies and innovations transformed imaging into a non-invasive tool that not only assesses solid tumor size and shape but also interrogates the spatial heterogeneity within tumors on the basis of their radiologic appearance, metabolism, and physiology. The overall goal of the Image Response Assessment Team (IRAT) Shared Resource is to enhance the scientific quality of clinical studies, by offering a single point of entry for Moffitt Cancer Center (MCC) members to access traditional and advanced quantitative image analysis services. To this end, efforts are organized around three Specific Aims, which are to: 1) maintain and improve the high reliability and fast turnaround times for RECIST (Response Evaluation Criteria in Solid Tumors) and other standard tumor assessment metrics; 2) improve therapeutic trials at MCC by translating research advances in radiomics and multi-parameter MRI (mpMRI) analyses into turnkey imaging biomarker services; and 3) provide members with access to non-traditional imaging endpoints for therapeutic trials. IRAT consists of five full-time staff and provides quantitative image-based tumor metrics to support investigator- initiated, cooperative group, and industry-sponsored clinical trials at MCC, and is part of the national consortium of Cancer Center IRATs. IRAT has essential roles in the MCC mission “to contribute to the prevention and cure of cancer,” by providing the support and services necessary to integrate both traditional and innovative imaging endpoints into clinical trials and by providing quality assurance and control throughout the process to yield scientifically valid results. With rapid advances in treatment paradigms such as immunotherapies, IRAT provides improved imaging endpoints to meet the needs of these cutting-edge studies of MCC members. IRAT has witnessed sustained increases in the volume of quantitative image response assessment services provided. A total of 298 new trials requiring imaging response assessment were activated in FY11-15, rising from 39 in FY11 to 65 in FY15. Developing an infrastructure for IRAT has permitted the pursuit of other funded trial opportunities that use advanced and/or investigational imaging techniques, analyses, and novel biomarkers. For example, IRAT is supporting multiple grant applications and funded projects by members investigating radiomic and mpMRI imaging biomarkers in retrospective and prospective clinical and pre-clinical studies. During the past project period, IRAT served 34 members from 4 MCC Programs. Overall usage by members was 94%, with 63% of total usage supporting members with peer- reviewed funding. IRAT-supported studies resulted in a total of 62 peer-reviewed scientific publications during this period.